Urology is a branch of medicine that deals with the diagnosis and treatment of diseases affecting the urinary tract of males and females, reproductive organs of males, as well as kidneys, ureters, bladder and prostate.
Urology is a wide-ranging speciality and deals with the diagnosis and treatment of conditions such as genitourinary cancers including prostate cancer, cystinosis including nephropathic cystinosis as well as benign prostatic hyperplasia, erectile dysfunction and kidney transplantation for end-stage renal disease.
Featured Learning Zones
Related news and insights
Bristol Myers Squibb announced that CheckMate -274, a pivotal Phase III trial evaluating Opdivo (nivolumab) after surgery in patients with high-risk, muscle-invasive urothelial carcinoma met its primary endpoints of improving disease-free survival (DFS) versus placebo in both all randomized patients and in patients whose tumors express PD-L1 in at least 1% of cells (programmed death-ligand 1).
AstraZeneca and MSD’s Lynparza (olaparib) has been recommended for marketing authorisation in the European Union (EU) for patients with metastatic castration-resistant prostate cancer (mCRPC) with breast cancer susceptibility gene 1/2 (BRCA1/2) mutations, a subpopulation of homologous recombination repair (HRR) gene mutations.
Final results from the Phase III PROfound trial showed AstraZeneca and MSD’s Lynparza (olaparib) demonstrated a statistically significant and clinically meaningful improvement in overall survival (OS) versus enzalutamide or abiraterone in men with metastatic castration-resistant prostate cancer (mCRPC) with BRCA1/2 or ATM gene mutations, a subpopulation of homologous recombination repair (HRR) gene mutations.